Organization
DalCor Pharmaceuticals
3 clinical trials
2 abstracts
Clinical trial
Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19Status: Completed, Estimated PCD: 2021-05-17
Clinical trial
A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE TrialStatus: Completed, Estimated PCD: 2021-10-01
Abstract
A RANDOMIZED CONTROLLED TRIAL OF THE UTILITY OF ULTRASONOGRAPHY TO GUIDE LOCAL STEROID INJECTION IN THE PAINFUL SHOULDER Org: DalCor Pharmaceuticals, CHUV, Lausanne, Switzerland, HiberCell, Estavayer-le-lac,
Abstract
AN EASY FUNCTIONAL CAPACITY EVALUATION IN CHRONIC LOW BACK PAIN Org: DalCor Pharmaceuticals, CHUV, Lausanne, Switzerland, Switzerland,